Oh yes they do care about other indications especially the potential buyer(s). For those existing conditions treated by cyclosporine or other CNIs, all they need is a phase3 trial to come up with a best in class choice for those other indications since Voclosporin has better safety and efficacy profile than cyclosporine or other CNIs and that will be another billions on top of Lupus Nephritis.This is the reason why I think the BO price will not be less than 40 bucks. Pick any sp between 40 and 100...jmo.
News 
Market Data 
Discover 
